These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38768736)

  • 1. Impact of an antimicrobial stewardship program indicator on the appropriateness of the empiric antibiotic treatment of urinary source Escherichia coli bacteraemia.
    Giménez-Pérez M; Hernández S; Padullés A; Boix-Palop L; Grau S; Badia JM; Ferrer R; Calbo E; Limón E; Pujol M; Horcajada JP;
    Int J Antimicrob Agents; 2024 Aug; 64(2):107202. PubMed ID: 38768736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential interventions for an antimicrobial stewardship bundle for Escherichia coli bacteraemia.
    Birrell MT; Horne K; Rogers BA
    Int J Antimicrob Agents; 2021 Apr; 57(4):106301. PubMed ID: 33588016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.
    Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Antimicrobial Stewardship and Molecular Rapid Diagnostic Tests on Antimicrobial Prescribing for Extended-Spectrum Beta-Lactamase- and Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae in Bloodstream Infection.
    Kunz Coyne AJ; Casapao AM; Isache C; Morales J; McCarter YS; Jankowski CA
    Microbiol Spectr; 2021 Oct; 9(2):e0046421. PubMed ID: 34704795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity.
    To KK; Lo WU; Chan JF; Tse H; Cheng VC; Ho PL
    Int J Infect Dis; 2013 Feb; 17(2):e120-4. PubMed ID: 23098812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antibiotic stewardship interventions in primary care on antimicrobial resistance of Escherichia coli bacteraemia in England (2013-18): a quasi-experimental, ecological, data linkage study.
    Aliabadi S; Anyanwu P; Beech E; Jauneikaite E; Wilson P; Hope R; Majeed A; Muller-Pebody B; Costelloe C
    Lancet Infect Dis; 2021 Dec; 21(12):1689-1700. PubMed ID: 34363774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community: an interrupted time-series analysis.
    Peñalva G; Fernández-Urrusuno R; Turmo JM; Hernández-Soto R; Pajares I; Carrión L; Vázquez-Cruz I; Botello B; García-Robredo B; Cámara-Mestres M; Domínguez-Camacho JC; Aguilar-Carnerero MM; Lepe JA; de Cueto M; Serrano-Martino MC; Domínguez-Jiménez MC; Domínguez-Castaño A; Cisneros JM;
    Lancet Infect Dis; 2020 Feb; 20(2):199-207. PubMed ID: 31767423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Metan G; Zarakolu P; Cakir B; Hascelik G; Uzun O
    Int J Antimicrob Agents; 2005 Sep; 26(3):254-7. PubMed ID: 16122910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of an antimicrobial stewardship program on urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Esteve-Palau E; Grau S; Herrera S; Sorlí L; Montero M; Segura C; Durán X; Horcajada JP
    Rev Esp Quimioter; 2018 Apr; 31(2):110-117. PubMed ID: 29521484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility profiles of gram-negative bacteria causing infections collected across India during 2014-2016: Study for monitoring antimicrobial resistance trend report.
    Veeraraghavan B; Jesudason MR; Prakasah JAJ; Anandan S; Sahni RD; Pragasam AK; Bakthavatchalam YD; Selvakumar RJ; Dhole TN; Rodrigues C; Roy I; Joshi S; Chaudhuri BN; Chitnis DS
    Indian J Med Microbiol; 2018; 36(1):32-36. PubMed ID: 29735823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.
    Van Aken S; Lund N; Ahl J; Odenholt I; Tham J
    Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.
    Toner L; Papa N; Aliyu SH; Dev H; Lawrentschuk N; Al-Hayek S
    World J Urol; 2016 Jul; 34(7):1031-7. PubMed ID: 26511749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing
    Benanti GE; Brown ART; Shigle TL; Tarrand JJ; Bhatti MM; McDaneld PM; Shelburne SA; Aitken SL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
    Deemer K; Grey J; Fronczek C; Marr K
    Am J Health Syst Pharm; 2020 Nov; 77(Supplement_4):S105-S110. PubMed ID: 32840305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
    Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
    Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
    Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
    Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the relationship between primary care antibiotic prescribing for urinary tract infections, Escherichia coli bacteraemia incidence and antimicrobial resistance: an ecological study.
    Lishman H; Costelloe C; Hopkins S; Johnson AP; Hope R; Guy R; Muller-Pebody B; Holmes A; Aylin P
    Int J Antimicrob Agents; 2018 Dec; 52(6):790-798. PubMed ID: 30145249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
    Lepeule R; Ruppé E; Le P; Massias L; Chau F; Nucci A; Lefort A; Fantin B
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1376-81. PubMed ID: 22214774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.
    Fernando MM; Luke WA; Miththinda JK; Wickramasinghe RD; Sebastiampillai BS; Gunathilake MP; Silva FH; Premaratna R
    BMC Infect Dis; 2017 Feb; 17(1):138. PubMed ID: 28187754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Peralta G; Sánchez MB; Garrido JC; De Benito I; Cano ME; Martínez-Martínez L; Roiz MP
    J Antimicrob Chemother; 2007 Oct; 60(4):855-63. PubMed ID: 17644532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.